

USSN: 10/712,859

- 2 -

PC25163A


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the current application.

Listing of Claims

Claims 1 – 16 (canceled).

Claim 17 (original): A method for reducing systemic inflammation comprising administering to a mammal, in need thereof, an effective amount of a compound of the formula:



I

wherein

n and m independently are integers from 2 to 9;

R₁, R₂, R₃, and R₄ independently are C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, and R₁ and R₂ together with the carbon to which they are attached, and R₃ and R₄ together with the carbon to which they are attached, independently can complete a carbocyclic ring having from 3 to 6 carbons;

Y₁ and Y₂ independently are COOH, CHO, tetrazole, and COOR₅ where R₅ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, substituted alkyl, alkenyl, or alkynyl;

and where the alkyl, alkenyl, and alkynyl groups may be substituted with one or two groups selected from halo, hydroxy, C₁-C₆ alkoxy, and phenyl, or a pharmaceutically acceptable salt thereof.

Claim 18 (original): A method according to Claim 17 wherein the mammal is a human.

USSN: 10/712,859

- 3 -


PC25163A

Claim 19 (original): A method according to Claim 18 wherein the compound inhibits proinflammatory cytokine induced CRP production.

Claim 20 (original): The method according to Claim 17 wherein the compound is 6,6'-oxybis(2,2-dimethylhexanoic acid) or a pharmaceutically acceptable salt thereof.

Claim 21 (original): A method according to Claim 20 wherein the mammal is a human.

Claim 22 (original): A method for reducing systemic inflammation comprising administering to a mammal, in need thereof, an effective amount of a pharmaceutical composition comprising a compound of the formula:



I

wherein

n and m independently are integers from 2 to 9;

R₁, R₂, R₃, and R₄ independently are C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, and R₁ and R₂ together with the carbon to which they are attached, and R₃ and R₄ together with the carbon to which they are attached, independently can complete a carbocyclic ring having from 3 to 6 carbons;

Y₁ and Y₂ independently are COOH, CHO, tetrazole, and COOR₅ where R₅ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, substituted alkyl, alkenyl, or alkynyl;

and where the alkyl, alkenyl, and alkynyl groups may be substituted with one or two groups selected from halo, hydroxy, C₁-C₆ alkoxy, and phenyl,

or a pharmaceutically acceptable salt thereof;

and a pharmaceutically acceptable diluent, carrier, or excipient.

Claim 23 (original): A method according to Claim 22 wherein the mammal is a human.

USSN: 10/712,859

- 4 -

PC25163A

Claim 24 (original): A method according to Claim 23 wherein the compound inhibits proinflammatory cytokine induced CRP production.

Claim 25 (original): A method according to Claim 22 wherein the compound is 6,6'-oxybis(2,2-dimethylhexanoic acid) or a pharmaceutically acceptable salt thereof.

Claim 26 (original): A method according to Claim 25 wherein the mammal is a human.

Claims 27-36 (canceled).